Probabilistic association learning

RESEARCH STUDY

PROBABILISTIC ASSOCIATION LEARNING, SCHIZOTYPAL PERSONALITY TRAITS AND STRIATAL FUNCTION

We are recruiting healthy adults between 18 and 45 years of age to take part in a study of the relationship among probabilistic association learning (a type of non-conscious learning), schizotypal personality traits (involving odd behaviours and/or beliefs in some people), striatal function (an area deep inside the brain shown to be important for this type of non-conscious learning) and genes important to striatal function.

All participants will be asked to complete (within two hours) three questionnaires, a computerized learning test, six brief “pencil and paper” cognitive tests and to provide a blood sample for genetic analysis. Some participants (based on their questionnaire scores) will be asked to come back to receive a functional magnetic resonance image scan of the brain.

Reimbursement of $20.00 per visit will be provided for your time and for out-of-pocket expenses.

If you have any questions or are interested in participating, please feel free to contact the research team.

Isabella Jacomb at 02 9399 1858, email i.jacomb@neura.edu.au

Dr Tom Weickert at 02 9399 1130, email: t.weickert@neura.edu.au

See what’s going on at NeuRA

FEEL THE BUZZ IN THE AIR? US TOO.

‘Progressive. Incurable. Terminal. Nothing matters… I am going to die.’

‘There are days that I just cry like a baby. I’m meant to be the provider, the strong one. No son should have to change the underwear of their 57 year old father.’ Shin Liu is a man you want to know... kind, articulate and with love in his heart. At 57 years old however, Shin has planned his funeral. Two years ago, Shin was diagnosed with motor neurone disease (MND). Unlike many cancers or heart disease, there is not a single thing the medical profession can do to stop MND. This excruciating disease twists and contorts the human body in the most horrific way, and it quickly destroys the ability to move, speak, swallow and breathe. Life expectancy post diagnosis is 2.5 years. But NeuRA researchers are making exciting progress toward it's defeat. After years of meticulous research, we've learnt that in more than 90% of MND cases a protein called TDP-43 is responsible for the changes in motor neurones. In pre-clinical (non-human) trials, we have found that this protein can be controlled by a specially engineered peptide sequence (i.e. medication) which has the potential to stop MND in its tracks. But here is the most exciting development… we are observing improvements in movement, behaviour and memory upon administering this medication! This is innovative, ground-breaking research and we need your help to accelerate this research, which will in time enable clinical trials in people living with MND. Will you support or research today?
APPEAL